Published: 11:48am, 8 Aug, 2018 Updated: 11:32pm, 8 Aug, 2018
Chinese biotech firm BeiGene closed its trading debut in Hong Kong down 1%. The stock was halted after the company said it had received a "cease and desist" letter from regulators over concerns about an undisclosed product that could be used to treat cancer.